Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guben Qushi II (also known as Guben Qushi II Granules) is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is primarily indicated for the treatment of bronchial asthma, specifically targeting patients diagnosed with the "Qi deficiency with Heat Dampness" pattern according to TCM principles. The formulation is administered as granules and is currently being evaluated in randomized controlled clinical trials (e.g., ChiCTR2400084804) to assess its clinical efficacy, safety, and underlying biological mechanisms using multi-omics techniques. The name "Guben Qushi" reflects its therapeutic goals: "Guben" refers to strengthening the body's vital energy or "root," while "Qushi" refers to the elimination of pathological dampness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guben Qushi II.